Vertex Newswire

Comprehensive Real-Time News Feed for Vertex.

Results 1 - 20 of 171 in Vertex

  1. Quick Update: New Hires, Recent Panel Discussion Emphasize Confluence Of Pharma And Big DataRead the original story w/Photo

    Wednesday Dec 24 | Forbes.com

    ... and big data that occurred earlier this month. First, several pharma companies announced important new hires: Vertex Pharmaceuticals announced that David Altshuler will be their new Executive Vice President of Global Research and Chief Scientific ...

    Comment?

  2. BioPlus Specialty Pharmacy Expands 'Regional Pharmaceutical Care Liaison' TeamRead the original story w/Photo

    Thursday Dec 18 | PRWeb

    ... inside sales team to support the Pacific Northwest. Most recently Bray was a hepatitis C therapeutic specialist with Vertex and for five years before that he was a hepatitis C therapeutic specialist with Gilead. He holds a Bachelor of Arts degree ...

    Comment?

  3. Vertex Releases Online Customer Reviews, Comments SystemRead the original story w/Photo

    Thursday Dec 18 | PRWeb

    Vertex announced today the release of Revrrb, a software service that allows Web developers and bloggers to add reviews, ratings, and comments to any Web page or site. Vertex Software of Austin, Texas, released the first version of its customer review and commenting service, Revrrb , for public use today.

    Comment?

  4. Patrick names new life science center board member at pivotal time for agencyRead the original story w/Photo

    Wednesday Dec 17 | Business Journal

    ... p capital and services provider for life sciences companies BioInnovation, has been named to fill the seat vacated by Vertex founder Josh Boger in July. Parker is also one of three co-founders of LabCentral,...

    Comment?

  5. On the Move: Recent hires and appointments at local life science firmsRead the original story w/Photo

    Monday Dec 15 | Business Journal

    ... chief communications officer, leading the global investor relations, public relations and patient advocacy functions. Vertex Pharmaceuticals in Boston (Nadsdaq: VRTX) has named former director David Altshuler as executive vice president of global ...

    Comment?

  6. Why Gilead Sciences, Inc. And AbbVie Are Keeping An Eye On Achillion Pharmaceuticals, Inc.Read the original story

    Thursday Dec 11 | BioSpace

    ... past five years, the focus for hepatitis C research has been on developing a functional cure. Prior to the launch of Vertex Pharmaceuticals ' Incivek in 2011, the side effect-laden combination of peginterferon and ribavirin cured just 50% of ...

    Comment?

  7. Why Gilead Sciences and AbbVie Care About This Tiny CompanyRead the original story w/Photo

    Thursday Dec 11 | The Motley Fool

    However, they might also want to keep an eye on Achillion Pharmaceuticals ( Advancing a cure Over the past five years, the focus for hepatitis C research has been on developing a functional cure. Prior to the launch of Vertex Pharmaceuticals ' Incivek in 2011, the side effect-laden combination of peginterferon and ribavirin cured just 50% of patients.

    Comment?

  8. City Council approves tax break for Innovation District tech companyRead the original story w/Photo

    Wednesday Dec 10 | Universal Hub

    ... several years ago, back when the local construction business had basically collapsed - and then $12 million to bring Vertex across the river from Cambridge. EDIT: Someone posted this gem of an Onion story: "States Now Offering Millions in Tax Breaks ...

    Comment?

  9. S&P 500 Movers: NBR, CELGRead the original story w/Photo

    Monday Dec 8 | Forbes.com

    ... year to date performance. Two other components making moves today are Denbury Resources (DNR), trading down 5.0%, and Vertex Pharmaceuticals (VRTX), trading up 2.4% on the day.

    Comment?

  10. Time to Buy This Dip in Gilead Sciences, Inc. Stock?Read the original story

    Monday Dec 8 | The Motley Fool

    ... by disruptive new therapies that go on to eventually completely displace their older counterparts. For example, Vertex Pharmaceuticals ( ) saw sales of its hepatitis C therapy Incivek plunge by 99% in the wake of Sovaldi's approval. And Johnson & ...

    Comment?

  11. $311,000 Drug Raises QuestionsRead the original story w/Photo

    Sunday Dec 7 | NBC Philadelphia

    ... $311,000 per year sticker price was a shock to O'Malley, but with insurance from his employer, and the drug company Vertex Pharmaceuticals picking up the tab for his annual deductible, his out-of-pocket cost is only a $15 per month co-pay. To make ...

    Comment?

  12. Agree To Buy Vertex Pharmaceuticals At $75, Earn 5.3% Using OptionsRead the original story w/Photo

    Thursday Dec 4 | Forbes.com

    ... market price. ( Do options carry counterparty risk? This and six other common options myths debunked ). So unless Vertex Pharmaceuticals, Inc. sees its shares fall 36.7% and the contract is exercised (resulting in a cost basis of $71.00 per share ...

    Comment?

  13. 10 stocks everyone will brag they ownRead the original story w/Photo

    Wednesday Dec 3 | USA Today

    ... Funny, they're all the stocks that went up. There are 10 stocks in the Standard & Poor's 500, including biotech Vertex Pharmaceuticals (VRTX) , Southwest Airlines (LUV) and Electronic Arts (EA) that you can be certain to hear people talk about ...

    Comment?

  14. Celgene, BioMarin and Vertex are RBC's Top Biotech BuysRead the original story w/Photo

    Monday Dec 1 | Barron's

    Yee directs investors to his three favorite biotech stocks: Celgene, BioMarin Pharmaceutical and Vertex Pharmaceuticals .

    Comment?

  15. Vertex price target raised to $148 from $122 at MaximRead the original story

    Nov 19, 2014 | Theflyonthewall.com

    Vertex price target raised to $148 from $122 at Maxim Maxim raised its price target for shares of Vertex Pharmaceuticals to $148 saying the company's cystic fibrosis franchise could be worth more than it thought after the Cystic Fibrosis Foundation sold its royalty stream from Vertex to Royalty Pharma for $3.3B.

    Comment?

  16. Don't expect the V Foundation to make a billion-dollar royalty deal a la the CFFRead the original story w/Photo

    Nov 25, 2014 | Business Journal

    Don't expect the V Foundation to make a billion-dollar royalty deal anytime in the near future; that's not a part of its playbook. Last week, the Cystic Fibrosis Foundation sold royalty rights to drugs by Vertex Pharmaceuticals for $3.3 billion , or 17 times its revenue from 2012.

    Comment?

  17. Cystic Fibrosis Foundation a Gets $3.3 Billion For Royaltiesa Read the original story

    Nov 23, 2014 | Chemical & Engineering News

    The Cystic Fibrosis Foundation has sold its royalty rights for cystic fibrosis drugs developed at Vertex Pharmaceuticals for $3.3 billion. The buyer is New York City-based Royalty Pharma , which acquires drug royalty interests.

    Comment?

  18. Big Pharma - Crony Capitalism Out of ControlRead the original story

    Nov 22, 2014 | Common Dreams

    Two recent news items about the voracious drug industry should call for a supine Congress to arouse itself and initiate investigations about the pay-or-die drug prices that are far too common. The first item- a page one story in the New York Times -was about the Cystic Fibrosis Foundation, which fifteen years ago invested $150 million in the biotechnology company Vertex Pharmaceuticals to develop a drug for this serious lung disease.

    Comment?

  19. Vertex Pharmaceuticals (MA) To Present At Deutsche Bank BioFEST On December 2Read the original story

    Nov 20, 2014 | BioSpace

    Vertex Pharmaceuticals Incorporated today announced that management will participate in a fireside chat at the Deutsche Bank BioFEST in Boston on December 2 at 8:45 a.m. ET. Management's remarks can be accessed live through Vertex's website at www.vrtx.com in the "Investors" section under the "Events and Presentations" link.

    Comment?

  20. Nasdaq 100 Movers: VRTX, ADSKRead the original story w/Photo

    Nov 21, 2014 | Forbes.com

    ... Year to date, Autodesk registers a 24.0% gain. And the worst performing Nasdaq 100 component thus far on the day is Vertex Pharmaceuticals (VRTX), trading down 1.4%. Vertex Pharmaceuticals is showing a gain of 49.8% looking at the year to date ...

    Comment?